• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA commish: Rising drug prices are a public health concern

October 3, 2017 By Sarah Faulkner

FDAThe FDA plans to tackle rising drug prices, according to the regulatory watchdog’s commissioner, Dr. Scott Gottlieb.

Taking action to regulate the cost of prescription medicines would belargely unprecedented for the agency, which usually sticks to deciding whether a drug is safe and effective.

But in a blog post this week, Gottlieb described high drug costs as “a public health concern that FDA should address.”

Specifically, the FDA plans to accelerate the approval of generic alternatives to costly drugs, in the hopes of boosting competition and pushing down prices.

“Any steps we can take to encourage the development of generic competitors to complex drugs will have an outsized impact on access, and prices,” Gottlieb said.

Traditional, the debate over drug prices has lived in the domain of Congress. Although both parties agree that rising drug prices are a problem, Democrats tend to fight for price controls and drug importation while Republicans push for increased competition and generics.

Now-president Donald Trump waded into the issue of drug pricing during his campaign, saying that drug companies are “getting away with murder” in regards to what they charge the government.

Earlier this year, just two weeks into the job, Gottlieb proposed the Drug Competition Action Plan and called on the FDA to speed up its application review process. At the time, the agency’s backlog included 2,640 applications. Nearly 1,500 of them were sent back to sponsors with requests for changes.

Gottlieb also testified before the House appropriations subcommittee that the FDA could regularly publish lists of older medicines that don’t have generic competition, to encourage generics-makers into the market.

“Simply put, too many patients are priced out of the medicines they need,” Gottlieb told the members of the committee, according to The Wall Street Journal. “While the FDA does not have a direct role in drug pricing, we can take steps to facilitate entry of lower-cost alternatives to the market, and increase competition.”

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat

IN CASE YOU MISSED IT

  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS